Paige, which helps diagnose cancer using computer vision trained with clinical image data, raises $45M Series B led by Healthcare Venture Partners
Dean Takahashi / VentureBeat :
Context & Ripple Effects
Paige's $45M Series B is the middle act of a funding arc that began with its $25M Series A and the Memorial Sloan Kettering deal giving it access to 25M pathology slides — the clinical data moat its computer-vision models are trained on. The round later closed at $70M after a $20M extension, pushing total raised past $95M.
What makes the arc notable is where it lands: a $100M Series C led by Casdin Capital and Johnson & Johnson Innovation, followed by FDA clearance of Paige's prostate-cancer detection program — turning the data-access strategy of 2018 into a regulated diagnostic product.
First-order effects
- Paige gains the capital to industrialize its slide-analysis platform beyond the Sloan Kettering dataset, moving from research-stage models toward clinically validated diagnostics.
Second-order effects
- The clinical-data-plus-compute template attracts adjacent players: Imagene AI later raises to detect cancer biomarkers directly from digitized biopsy images, and Verana Health's big-data clinical-study platform shows specialty-medicine data platforms becoming their own funding category.
Third-order effects
- If the pattern holds — exclusive hospital data deals funding AI, then FDA clearance monetizing it — computational pathology consolidates around startups holding both large annotated archives and regulatory wins, with hospital systems as gatekeepers of the training data.
The trend: Cancer diagnostics is shifting toward AI companies that pair exclusive clinical-image datasets with regulatory clearance as the route to market.